Sign or Symptom – Talk Bio

Rapport Reveals Promising Phase 2a Data for RAP-219 Epilepsy Pill, Plans Phase 3 Trials

1 month ago talkbio0Tagged anti-seizure medication, Clinical Development, drug-resistant epilepsy, Epilepsy, focal onset seizures, RAP-219, Rapport Therapeutics, Seizures

Rapport Therapeutics; RAP-219; epilepsy; seizure reduction; Phase 2a clinical trial; focal onset seizures; Phase 3 trials; anti-seizure medication; drug-resistant epilepsy; clinical development

Fierce Biotech Fundraising Tracker ’25: CHARM attracts $80M; Wugen reels in $115M

1 month ago talkbio0Tagged AI drug design, charmed, Drug Development, Leukemia, Myelocytic, Acute, Menin Inhibitor, NVIDIA, Series B funding, venture capital, Wugen

CHARM Therapeutics; AI drug design; menin inhibitor; acute myeloid leukemia (AML); Series B funding; venture capital; biotech fundraising; Wugen; NVIDIA; drug development

FDA Approves Tonix’s Tonmya: First New Fibromyalgia Drug in Over 15 Years

2 months ago talkbio0Tagged Analgesics, Non-Narcotic, Approved, Chronic pain, Clinical Trials, cyclobenzaprine, Fibromyalgia, Hairy Cell Leukemia, Phase 3, sublingual tablets, Tonix, Tonmya, United States Food and Drug Administration

Tonmya; FDA approval; fibromyalgia; Tonix Pharmaceuticals; non-opioid analgesic; cyclobenzaprine HCl sublingual tablets; chronic pain; phase 3 clinical trials

Vertex Drops Next-Generation Pain Drug After Phase 2 Failure, Casts Doubt on Broader Journavx Expansion

2 months ago talkbio0Tagged Acute onset pain, Approved, Drug Development, Journavx, non-opioid pain drugs, Pain management, Peripheral neuropathic pain, Sodium Channel Blockers, United States Food and Drug Administration, VX-993

Vertex Pharmaceuticals; Journavx; VX-993; pain management; acute pain; phase 2 clinical trial; sodium channel inhibitor; non-opioid pain drugs; FDA approval; peripheral neuropathic pain; drug development

Praxis touts ‘best-in-disease’ epilepsy data, but shares dip

2 months ago talkbio0Tagged anti-seizure medication, Clinical Research, Clinical Trials, Epilepsy, focal onset seizures, Market, Praxis Precision Medicines, Radiant heater, Seizures, vormatrigine

Praxis Precision Medicines; epilepsy; vormatrigine; RADIANT study; focal onset seizures; Phase 2 trial; seizure reduction; clinical trial; anti-seizure medication; stock market

Bayer’s Lynkuet (elinzanetant) Wins First-in-World Approval in UK, Challenging Astellas’ Hot Flash Drug

3 months ago talkbio0Tagged Approved, Astellas, Bayer, Elinzanetant, Hot flushes, Lynkuet, Menopause, MHRA, non-hormonal therapy, UK, vasomotor symptom

Bayer; elinzanetant; Lynkuet; menopause; hot flashes; vasomotor symptoms; Astellas; non-hormonal therapy; MHRA approval; UK first approval

Leap Therapeutics Slashes 75% of Workforce, Ends Clinical Trial, Considers Strategic Options

4 months ago talkbio0Tagged Biotech Layoffs, Clinical Trials, FL-501, Flatulence, LEAP, Sirexatamab, strategic alternatives

Leap Therapeutics; workforce reduction; biotech layoffs; clinical trial; strategic alternatives; sirexatamab; FL-501; R&D wind down

Amgen Adjusts Phase 3 Dosing for MariTide After Midstage Side Effects Concerns

4 months ago talkbio0Tagged Adverse event, amgen, Clinical Trials, Dosage, Escalation, gastric inhibitory polypeptide receptor, GLP-1 receptor, MariTide, Obesity, Phase 3, Vomiting

Amgen; MariTide; Phase 3; obesity treatment; dose escalation; vomiting; adverse events; clinical trial; GLP-1 receptor; GIP receptor

Eli Lilly Acquires SiteOne for Up to $1B to Expand Non-Opioid Pain Pipeline

5 months ago talkbio0Tagged Acquisition, Chronic pain, Drug Industry, eli lilly, Nav1.8 inhibitor, neuroscience pipeline, non-opioid pain treatment, SiteOne Therapeutics, STC-004

Eli Lilly; SiteOne Therapeutics; non-opioid pain treatment; STC-004; acquisition; Nav1.8 inhibitor; chronic pain; neuroscience pipeline; Vertex; pharmaceutical industry

Eroding Immunity: Vaccine Hesitancy and Cynicism With Paul Offit

5 months ago talkbio0Tagged cynicism, Immune response, mandates, Misinformation, Offit, Paul Offit, Urinary hesitation, Vaccines

Vaccines, Urinary hesitation, Offit, cynicism, Misinformation, Immune response, Paul Offit, mandates